A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This is an open-label, multicenter Phase 2 study evaluating Navlimetostat (BMS-986504) in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which Navlimetostat (BMS-986504) is given with other anti-cancer agents. The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of Navlimetostat (BMS-986504) alone and in combination regimens.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Solid Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Bristol-Myers Squibb
- Last updated on ClinicalTrials.gov
- November 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 1
- Emory University - Winship Cancer Institute · Atlanta, GA
Maryland · 1
- Johns Hopkins Hospital · Baltimore, MD
New York · 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone · New York, NY
- Memorial Sloan Kettering Cancer Center · New York, NY
Texas · 1
- University of Texas MD Anderson Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.